Femasys shares are trading higher after the company announced FDA approval of its IDE for the pivotal clinical trial of FemBloc permanent birth control, a non-surgical alternative for women.
Portfolio Pulse from Benzinga Newsdesk
Femasys announced FDA approval of its IDE for the pivotal clinical trial of FemBloc permanent birth control, a non-surgical alternative for women, leading to higher trading of its shares.
June 26, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Femasys shares are trading higher after FDA approval of its IDE for the pivotal clinical trial of FemBloc permanent birth control.
The FDA approval of Femasys' IDE for the pivotal clinical trial of FemBloc is a significant milestone for the company, as it brings the product closer to market. This positive news has led to an increase in the trading of Femasys shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100